Skip navigation

 Login or Register | Member Centre

GlobeInvestorGOLD Canada's most comprehensive investment tool.

 
Change Symbol: Lookup Trade Now

Amgen | Headlines

  • Vol:
  • Last Trade:
Search found 65 documents NextNext
1: Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
PR NEWSWIRE, February 8, 2010 06:20 PM

2: Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91
PR NEWSWIRE, January 25, 2010 04:07 PM

3: Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
PR NEWSWIRE, January 21, 2010 09:00 AM

4: Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results
PR NEWSWIRE, January 20, 2010 04:13 PM

5: Amgen Donates $2 Million, Establishes Earthquake Relief Program
PR NEWSWIRE, January 14, 2010 12:57 PM

6: Amgen to Present at Lazard Capital Healthcare Conference
PR NEWSWIRE, November 16, 2009 06:06 PM

7: Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
PR NEWSWIRE, November 12, 2009 09:01 AM

8: Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
PR NEWSWIRE, November 5, 2009 08:03 AM

9: Call for Applications: The Amgen Award for Science Teaching Excellence
PR NEWSWIRE, November 4, 2009 12:22 PM

10: Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
PR NEWSWIRE, October 30, 2009 08:44 PM

NextNext
 

Search using one or more of the following options:

Symbol Lookup
 
 
  Search Tips
 
  * Can only be used when searching The Globe and Mail and newswires.

Back to top